Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase activity:
- Shares Purchased: 600,000 Ordinary shares of 25 pence each.
- Purchase Date: September 19, 2008.
- Price per Share: 1,193.05 pence.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,219,463,982 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of the Company's share capital through the cancellation of 600,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,219,463,982) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.09%).
- Note that this filing is a regulatory disclosure of a capital transaction and does not contain operational or financial performance data.